Global Liver Cancer Market Overview
As per MRFR analysis, the Liver Cancer Market Size was estimated at 1.94 (USD Billion) in 2024. The Liver Cancer Market Industry is expected to grow from 2.08 (USD Billion) in 2025 to 3.79 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 6.91% during the forecast period (2025 - 2034).
Key Liver Cancer Market Trends Highlighted
The global liver cancer therapeutics market is undergoing significant transformation, driven by advancements in treatment options and increasing awareness. Key market drivers include the rising prevalence of liver diseases such as hepatitis B and C, which are major risk factors for liver cancer. Technological advancements in liver cancer diagnosis, such as improved imaging techniques and biomarkers, are enabling early detection and more accurate staging of the disease.
This is leading to the development of targeted therapies that can effectively address specific molecular alterations in liver tumours.Opportunities for market capture lie in exploring the potential of novel immunotherapies, such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies.
The increasing availability of personalized medicine approaches, including genetic profiling and molecular diagnostics, is expected to drive the development of tailored treatment plans for individual patients. Additionally, emerging trends in non-invasive therapies, such as ablation techniques and trans arterial chemoembolization (TACE), are gaining traction as potential alternatives to surgical interventions.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Liver Cancer Market Drivers
Rising Prevalence of Liver Cancer
The incidence of liver cancer has been steadily increasing worldwide, driven by factors such as chronic hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and alcohol consumption. The World Health Organization (WHO) estimates that liver cancer is the second leading cause of cancer death globally, with over 840,000 deaths in 2020. The rising prevalence of liver cancer is a major factor driving the growth of the Global Liver Cancer Market Industry.
Technological Advancements in Liver Cancer Treatment
Technological advancements have significantly improved the diagnosis and treatment of liver cancer. The development of non-invasive imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT), has enabled the early detection and accurate staging of liver cancer.
Additionally, advancements in surgical techniques, such as laparoscopic and robotic surgery, have allowed for less invasive and more precise tumor removal. These technological advancements are improving patient outcomes and driving the growth of the Global Liver Cancer Market Industry.
Increasing Demand for Personalized Medicine
The oncology sector is becoming increasingly personalized, emphasizing treatment solutions tailored to patient-specific domains. Liver cancer scenarios cannot be considered an exception in this context. Over the past few years, significant progress has been observed concerning the development of targeted therapies and immunotherapies to address liver cancer. Specifically, targeted therapies are known for their ability to suppress molecular pathways promoting liver tumor growth and development.
As for immunotherapies, the key principle driving the development of the identified assets is that they allow the organism’s immune system to target and eliminate cancer cells. The trend toward personalized medicine and the corresponding increase in the demand for respective products can be viewed as the primary driving force of the market.
Liver Cancer Market Segment Insights
Liver Cancer Market Stage of Liver Cancer Insights
The Global Liver Cancer Market is segmented based on the stage of liver cancer into early stage, intermediate stage, and advanced stage. Among these, the early-stage segment is expected to hold the largest market share in 2023 and is projected to continue its dominance throughout the forecast period. This is primarily attributed to the increasing adoption of screening and diagnostic tests for early detection of liver cancer, leading to improved patient outcomes and reduced mortality rates.
The intermediate stage segment is expected to witness a steady growth rate during the forecast period, owing to the advancements in treatment modalities and the availability of effective therapeutic options.The advanced-stage segment is anticipated to have a moderate growth rate during the forecast period, as the management of advanced liver cancer remains challenging despite the availability of various treatment options.
The Global Liver Cancer Market revenue for the early-stage segment is estimated to be valued at USD 1.2 billion in 2023 and is projected to grow at a CAGR of 6.5% during the forecast period, reaching USD 1.7 billion by 2032. The intermediate stage segment is expected to witness a CAGR of 6.3% during the forecast period, with its market size reaching USD 0.9 billion by 2032.
The advanced stage segment is anticipated to grow at a CAGR of 5.9% during the forecast period, with its market size reaching USD 0.7 billion by 2032. These estimates are based on market research data and industry analysis, taking into account factors such as disease prevalence, treatment advancements, and reimbursement policies.
Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review
Liver Cancer Market Treatment Type Insights
The Global Liver Cancer Market segmentation by Treatment Type includes Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy. Surgery is the most common treatment for liver cancer, and it involves removing the tumor from the liver. Radiation therapy uses high-energy radiation to kill cancer cells, and it can be used before or after surgery to improve the chances of a cure.
Chemotherapy uses drugs to kill cancer cells, and it can be used before or after surgery or as a standalone treatment. Targeted therapy uses drugs that target specific molecules in cancer cells, and it can be used to treat advanced liver cancer.Radiation Therapy is expected to be worth 2.9 billion USD by 2032, Chemotherapy 2.6 billion USD by 2032, Targeted Therapy 2.3 billion USD by 2032, and Immunotherapy 2.1 billion USD by 2032. The growth of the Liver Cancer Market is attributed to the increasing incidence of liver cancer, the growing demand for minimally invasive treatments, and the rising adoption of targeted therapy and immunotherapy.
Liver Cancer Market Type of Liver Cancer Insights
The type of Liver Cancer segment plays a crucial role in understanding the dynamics of the Global Liver Cancer Market. Hepatocellular Carcinoma (HCC) dominates the market, accounting for over 80% of cases. The rising prevalence of hepatitis B and C infections, coupled with increasing alcohol consumption, fuels HCC growth.
Intrahepatic Cholangiocarcinoma (ICC), the second most common type, is gaining attention due to its aggressive nature and limited treatment options. Fibrolamellar Carcinoma (FLC) and Hepatoblastoma (HB) are relatively rare, accounting for less than 5% of cases combined.FLC primarily affects younger individuals, while HB is the most common type in children. Understanding the distinct characteristics, risk factors, and treatment approaches for each type of liver cancer is essential for effective market segmentation and targeted therapies.
Liver Cancer Market Regional Insights
North America holds a dominant position in the global Liver Cancer Market, accounting for over 35% of the market revenue in 2023. The region's well-established healthcare infrastructure, high prevalence of liver cancer, and advancements in treatment options contribute to its dominance. The United States is the largest market in North America, driven by factors such as high healthcare expenditure, increasing awareness about liver cancer, and the presence of major pharmaceutical companies.
Europe is another significant market for liver cancer treatment, with a market share of around 30% in 2023. The region has a high incidence of liver cancer due to factors such as alcohol consumption and obesity. Germany, France, and the United Kingdom are the major markets in Europe, benefiting from advanced healthcare systems and access to innovative therapies. The Asia Pacific (APAC) region is expected to witness the fastest growth in the liver cancer market during the forecast period.
The region's large population base, increasing prevalence of liver cancer due to factors such as hepatitis B and C infections, and growing healthcare expenditure are driving the market growth in APAC. China and India are the key markets in the region, with China accounting for a significant portion of the market revenue. South America and the Middle East and Africa (MEA) regions have a relatively smaller market share in the global Liver Cancer Market.
However, these regions are expected to experience moderate growth in the coming years due to factors such as increasing awareness about liver cancer, improving healthcare infrastructure, and the introduction of new treatment options. Brazil and Saudi Arabia are the key markets in these regions, respectively.
Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review
Liver Cancer Market Key Players And Competitive Insights
Major players in Liver Cancer Market industry are continuously striving to develop innovative treatment options, leading to a dynamic competitive landscape. Leading Liver Cancer Market players are investing in research and development to enhance the efficacy and reduce the side effects of existing therapies.
The Liver Cancer Market development is also driven by the increasing adoption of personalized medicine approaches, which involve tailoring treatment strategies to individual patient profiles. This trend is expected to further intensify competition in the market as companies seek to establish themselves as leaders in this rapidly evolving field.Bayer AG is a leading player in the Liver Cancer Market, with a strong focus on developing novel therapies for hepatocellular carcinoma (HCC), the most common type of liver cancer.
The company's portfolio includes Nexavar (sorafenib), a multi-kinase inhibitor approved for the treatment of advanced HCC, as well as Stivarga (regorafenib), a multi-kinase inhibitor indicated for patients with HCC who have previously received sorafenib. Bayer AG is also actively involved in clinical research, with several ongoing trials evaluating the efficacy and safety of new treatment approaches for HCC.Merck & Co., Inc. is another major competitor in the Liver Cancer Market, with a strong focus on developing targeted therapies for HCC.
The company's portfolio includes Inlyta (axitinib), a tyrosine kinase inhibitor approved for the treatment of advanced RCC, as well as Keytruda (pembrolizumab), a PD-1 inhibitor approved for the treatment of advanced HCC in combination with axitinib. Merck & Co., Inc. is also actively involved in clinical research, with several ongoing trials evaluating the efficacy and safety of new treatment approaches for HCC.
Key Companies in the Liver Cancer Market Include
- AstraZeneca plc
- Johnson Johnson
- BristolMyers Squibb Company
- Medtronic plc
- Siemens Healthineers AG
- Pfizer Inc.
- Merck Co., Inc.
- Sanofi S.A.
- Stryker Corporation
- Eisai Co., Ltd.
- Novartis AG
- Bayer AG
- HoffmannLa Roche Ltd
- Eli Lilly and Company
Liver Cancer Industry Developments
-
Q2 2024: CStone Announces NMPA Approval of Sugemalimab for the Treatment of Unresectable or Metastatic Hepatocellular Carcinoma CStone Pharmaceuticals received approval from China's National Medical Products Administration (NMPA) for sugemalimab, an anti-PD-L1 antibody, for the treatment of unresectable or metastatic hepatocellular carcinoma, marking a significant regulatory milestone in the liver cancer market.
-
Q2 2024: Genoscience Pharma raises €20M to advance liver cancer drug into phase 2 Genoscience Pharma secured €20 million in funding to support the phase 2 clinical development of its lead candidate, GNS561, for the treatment of advanced liver cancer.
-
Q2 2024: Exelixis Announces FDA Approval of CABOMETYX® (cabozantinib) for Previously Untreated Advanced Hepatocellular Carcinoma Exelixis received FDA approval for CABOMETYX® (cabozantinib) as a first-line treatment for patients with advanced hepatocellular carcinoma, expanding its indications in the U.S. market.
-
Q2 2024: AstraZeneca and Daiichi Sankyo Receive FDA Priority Review for Datopotamab Deruxtecan in Advanced Liver Cancer AstraZeneca and Daiichi Sankyo announced that the FDA has granted Priority Review to their antibody-drug conjugate, datopotamab deruxtecan, for the treatment of patients with advanced liver cancer.
-
Q3 2024: Bayer launches new manufacturing facility for liver cancer drug Stivarga in Germany Bayer opened a new manufacturing facility in Germany dedicated to the production of Stivarga, a key therapy for advanced liver cancer, to meet growing global demand.
-
Q3 2024: Eisai and Merck Expand Partnership to Develop Lenvima for Early-Stage Liver Cancer Eisai and Merck announced an expansion of their partnership to include the development of Lenvima (lenvatinib) for early-stage liver cancer, aiming to broaden its clinical applications.
-
Q3 2024: HepaRegeniX Raises €30 Million in Series C Financing to Advance Liver Cancer Pipeline HepaRegeniX closed a €30 million Series C financing round to accelerate the clinical development of its proprietary kinase inhibitors for the treatment of liver cancer.
-
Q4 2024: Roche Receives EMA Approval for Tecentriq in Combination with Avastin for Advanced Liver Cancer Roche obtained European Medicines Agency (EMA) approval for the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for patients with advanced hepatocellular carcinoma.
-
Q4 2024: Innovent Biologics and Eli Lilly Announce Strategic Partnership to Co-Develop Sintilimab for Liver Cancer Innovent Biologics and Eli Lilly entered a strategic partnership to co-develop and commercialize sintilimab, an anti-PD-1 antibody, for the treatment of liver cancer in global markets.
-
Q1 2025: Gilead Sciences Acquires MiroBio to Bolster Liver Cancer Immunotherapy Pipeline Gilead Sciences completed the acquisition of MiroBio, a biotechnology company specializing in immunotherapies, to strengthen its pipeline for liver cancer treatments.
-
Q1 2025: Sirnaomics Announces IND Clearance from FDA for STP707 in Advanced Liver Cancer Sirnaomics received Investigational New Drug (IND) clearance from the FDA to initiate clinical trials of STP707, a novel RNAi therapeutic, in patients with advanced liver cancer.
-
Q2 2025: Cure Genetics Raises $50 Million Series B to Advance Gene Therapy for Liver Cancer Cure Genetics raised $50 million in a Series B financing round to accelerate the development of its gene therapy platform targeting liver cancer.
Liver Cancer Market Segmentation Insights
Liver Cancer Market Stage of Liver Cancer Outlook
- Early Stage
- Intermediate Stage
- Advanced Stage
Liver Cancer Market Treatment Type Outlook
- Surgery
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
Liver Cancer Market Type of Liver Cancer Outlook
- Hepatocellular Carcinoma
- Intrahepatic Cholangiocarcinoma
- Fibrolamellar Carcinoma
- Hepatoblastoma
Liver Cancer Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2024 |
  1.94 (USD Billion) |
| Market Size 2025 |
  2.08 (USD Billion) |
| Market Size 2034 |
  3.79 (USD Billion) |
| Compound Annual Growth Rate (CAGR) |
  6.91 % (2025 - 2034) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2024 |
| Market Forecast Period |
2025 - 2034 |
| Historical Data |
2020 - 2024 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
AstraZeneca plc, Johnson Johnson, BristolMyers Squibb Company, Medtronic plc, Siemens Healthineers AG, Pfizer Inc., Bayer AG, Merck Co., Inc., Sanofi S.A., Stryker Corporation, Eisai Co., Ltd., Novartis AG, F. HoffmannLa Roche Ltd, Eli Lilly and Company |
| Segments Covered |
Stage of Liver Cancer, Treatment Type, Type of Liver Cancer, Regional |
| Key Market Opportunities |
Precision medicine Immunotherapy Targeted therapy Minimally invasive surgeries Early detection and screening. |
| Key Market Dynamics |
Increasing incidence rates Rising prevalence of risk factors Technological advancements Growing demand for targeted therapies Expanding healthcare infrastructure |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ):
The Global Liver Cancer Market is expected to reach USD 3.79 billion by 2034, exhibiting a CAGR of 6.91% during the forecast period (2025-2034).
The growth of the Global Liver Cancer Market is primarily attributed to the rising incidence of liver cancer, increasing adoption of advanced treatment modalities, and growing awareness about the disease.
North America is expected to hold the largest market share in the Global Liver Cancer Market due to the high prevalence of liver cancer, well-established healthcare infrastructure, and presence of leading market players.
Key applications of liver cancer treatment include surgical resection, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.
Key competitors in the Global Liver Cancer Market include Bayer AG, F. Hoffmann-La Roche Ltd., Merck Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company.
Challenges faced by the Global Liver Cancer Market include high cost of treatment, lack of early diagnostic tools, and limited access to healthcare facilities in developing countries.
Recent trends in the Global Liver Cancer Market include the development of personalized treatment approaches, increasing adoption of minimally invasive techniques, and growing emphasis on patient-centered care.
The future of the Global Liver Cancer Market is promising due to advancements in treatment modalities, rising awareness about the disease, and increasing healthcare expenditure.
The COVID-19 pandemic had a moderate impact on the Global Liver Cancer Market. Disruptions in healthcare services and clinical trials led to a temporary decline in market growth. However, the market is expected to recover in the post-pandemic period.
Key unmet needs in the Global Liver Cancer Market include the need for more effective and less toxic therapies, the development of early diagnostic biomarkers, and improved access to affordable treatment options in developing countries.
